Ipsen announces the launch of an Employee Shareholding Plan
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen – June 2024 – Monthly information relative to the...
Half-year statement of IPSEN liquidity agreement – 2024 06 30
Ipsen expands collaboration and license agreement for development of Cabometyx®...
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class...
You are now leaving the Ipsen group global website. To continue, please click on Continue?
How easy was it to navigate Ipsen website and locate the information you were seeking?
